Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patient preference trial of everolimus + exemestane versus capecitabine + bevacizumab in advanced hormone receptor-positive HER2-negative breast cancer
2013-005329-22Phase 4Completed
- Sponsor
- iOMEDICO
- Start
- Jun 2014
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in breast cancer comparing Everolimus + exemestane with Capecitabine + bevacizumab (2 arms). Primary endpoint: Patient preference between treatment combinations. Started Jun 2014; status: completed.
02
Drugs
everolimusexemestanecapecitabinebevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2013-005329-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005329-22.